[go: up one dir, main page]

PE20151091A1 - Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes - Google Patents

Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes

Info

Publication number
PE20151091A1
PE20151091A1 PE2015001179A PE2015001179A PE20151091A1 PE 20151091 A1 PE20151091 A1 PE 20151091A1 PE 2015001179 A PE2015001179 A PE 2015001179A PE 2015001179 A PE2015001179 A PE 2015001179A PE 20151091 A1 PE20151091 A1 PE 20151091A1
Authority
PE
Peru
Prior art keywords
immune
cancer
treatment
autoimmune diseases
inducing agents
Prior art date
Application number
PE2015001179A
Other languages
English (en)
Inventor
Milan Bruncko
Yujia Dai
Hong Ding
George A Doherty
Steven W Elmore
Lisa Hasvold
Laura Hexamer
Aaron R Kunzer
Robert A Mantei
William J Mcclellan
Chang H Park
Cheol-Min Park
Andrew M Petros
Xiaohong Song
Andrew J Souers
Gerard Sullivan
Zhi-Fu Tao
Gary T Wang
Le Wang
Xilu Wang
Michael D Wendt
Original Assignee
Abbvie Inc
Inst Medical W & E Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41809142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151091(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc, Inst Medical W & E Hall filed Critical Abbvie Inc
Publication of PE20151091A1 publication Critical patent/PE20151091A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/30—Nitrogen atoms non-acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto o una sal terapeuticamente aceptable del mismo, en donde el compuesto se selecciona de: 4-(4-((4'-cloro-1,1'-bifenil-2-il)metil)piperazin-1-il)-2-(3-((dimetilamino)metil)fenoxi)-N-((3-nitro-4-((tetrahidro-2H-piran-4 ilmetil)amino)fenil)sulfonil)benzamida; 4-(4-((4'-cloro-1,1'-bifenil-2-il)metil)piperazin-1-il)-2-(3-(metilamino)fenoxi)-N-((3-nitro-4-((tetrahidro-2H-piran-4-ilmetil)amino)fenil)sulfonil)benzamida; 4-(4-((4'-cloro-1,1'-bifenil-2-il)metil)piperazin-1-il)-2-(3-clorofenoxi)-N-((3-nitro-4-((tetrahidro-2H-piran-4-ilmetil)amino)fenil)sulfonil)benzamida
PE2015001179A 2008-12-04 2009-12-04 Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes PE20151091A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11984408P 2008-12-04 2008-12-04

Publications (1)

Publication Number Publication Date
PE20151091A1 true PE20151091A1 (es) 2015-09-05

Family

ID=41809142

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015001179A PE20151091A1 (es) 2008-12-04 2009-12-04 Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes
PE2011001147A PE20120136A1 (es) 2008-12-04 2009-12-04 Compuestos derivados de n-acilsulfonamidas como inhibidores de bcl-2

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011001147A PE20120136A1 (es) 2008-12-04 2009-12-04 Compuestos derivados de n-acilsulfonamidas como inhibidores de bcl-2

Country Status (26)

Country Link
EP (2) EP3112361A1 (es)
JP (2) JP5699306B2 (es)
KR (2) KR101792640B1 (es)
CN (2) CN102307622B (es)
AU (1) AU2009322269B2 (es)
BR (1) BRPI0922314A2 (es)
CA (1) CA2744708C (es)
CL (1) CL2011001281A1 (es)
CO (1) CO6382143A2 (es)
CR (2) CR20170289A (es)
DO (2) DOP2011000155A (es)
EC (1) ECSP11011173A (es)
ES (1) ES2622344T3 (es)
IL (2) IL212879B (es)
MX (2) MX2011005925A (es)
MY (2) MY166546A (es)
NZ (1) NZ592802A (es)
PE (2) PE20151091A1 (es)
PH (1) PH12015502017A1 (es)
RU (1) RU2527450C2 (es)
SG (1) SG10201500678RA (es)
TW (2) TWI600650B (es)
UA (1) UA108193C2 (es)
UY (1) UY32681A (es)
WO (1) WO2010065824A2 (es)
ZA (1) ZA201103807B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MX363470B (es) * 2008-12-05 2019-03-25 Abbvie Inc Derivados de sulfonamida como agentes inductores de apoptosis selectiva de bcl-2 para el tratamiento del cancer y enfermedades inmunes.
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
SG172391A1 (en) 2009-01-19 2011-07-28 Abbott Lab Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
MY155645A (en) * 2009-05-26 2015-11-13 Abbvie Bahamas Ltd Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) * 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
SG186077A1 (en) 2010-06-03 2013-01-30 Pharmacyclics Inc The use of inhibitors of bruton's tyrosine kinase (btk)
UA113500C2 (xx) * 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
KR102095698B1 (ko) * 2010-10-29 2020-04-01 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
NZ708508A (en) * 2010-11-23 2016-06-24 Abbvie Bahamas Ltd Methods of treatment using selective bcl-2 inhibitors
CA2817629C (en) 2010-11-23 2019-08-13 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
WO2012162365A1 (en) * 2011-05-25 2012-11-29 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic bcl inhibitors
CN103958508B (zh) 2011-10-14 2019-02-12 艾伯维公司 用于治疗癌症以及免疫与自身免疫性疾病的细胞凋亡诱导剂
KR20230109775A (ko) * 2011-10-19 2023-07-20 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(btk)의 억제제의 용도
WO2013185202A1 (en) * 2012-06-14 2013-12-19 Beta Pharma Canada Inc Apoptosis inducers
US10954567B2 (en) 2012-07-24 2021-03-23 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)
US8883784B2 (en) * 2012-08-13 2014-11-11 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
HRP20181273T1 (hr) * 2013-03-13 2018-11-16 Abbvie Inc. Postupci za pripravu sredstva koje inducira apoptozu
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
CN104250233B (zh) * 2014-08-29 2016-03-16 湖南华腾制药有限公司 一种4-叔丁氧羰基-2-环丙基吗啉的制备方法
UA125245C2 (uk) 2014-10-06 2022-02-09 Вертекс Фармасьютикалз Інкорпорейтед Модулятори регулятора трансмембранної провідності при муковісцидозі
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
WO2017173274A1 (en) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2017305508B2 (en) 2016-08-05 2021-01-07 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors
RS62670B1 (sr) 2016-09-30 2021-12-31 Vertex Pharma Modulator transmembranskog regulatora provodnosti cistične fibroze, farmaceutske kompozicije, metode lečenja i proces izrade modulatora
MD3551622T2 (ro) 2016-12-09 2021-03-31 Vertex Pharma Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului
EP3565815B1 (en) * 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
CA3057886A1 (en) 2017-04-18 2018-10-25 Shanghai Fochon Pharmaceutical Co., Ltd. Bcl-2 inhibitors as apoptosis-inducing agents
EP3634402A1 (en) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019018395A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated METHODS OF TREATING CYSTIC FIBROSIS
CA3071278A1 (en) 2017-08-02 2019-02-07 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
SG11202001553UA (en) * 2017-08-23 2020-03-30 Newave Pharmaceutical Inc Condensed heterocyclic derivatives as bcl-2 inhibitors for the treatment of neoplastic diseases
EP3697774A1 (en) 2017-10-19 2020-08-26 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
JP7245834B2 (ja) 2017-12-08 2023-03-24 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス
KR20250008139A (ko) 2018-01-10 2025-01-14 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
WO2019185025A1 (zh) * 2018-03-30 2019-10-03 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11420968B2 (en) 2018-04-29 2022-08-23 Beigene, Ltd. Bcl-2 inhibitors
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
CN110772640B (zh) 2018-07-31 2023-02-03 苏州亚盛药业有限公司 Bcl-2抑制剂与利妥昔单抗和/或苯达莫司汀或与CHOP联合的协同抗肿瘤作用
US11491167B2 (en) 2018-07-31 2022-11-08 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
EP3672594B1 (en) 2018-07-31 2021-09-29 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
WO2020041406A1 (en) 2018-08-22 2020-02-27 Newave Pharmaceutical Inc. Bcl-2 inhibitors
CN112888687B (zh) * 2018-10-29 2023-01-24 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
CN109776414B (zh) * 2019-01-02 2022-04-22 山东大学 一种Bcl-2蛋白抑制剂及其制备方法和应用
JP7558977B2 (ja) 2019-05-24 2024-10-01 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド メチル基及びトリフルオロメチル基を含む二置換スルファミド系選択的ｂｃｌ－２阻害剤
CN112661751B (zh) * 2019-10-16 2024-06-14 南京天印健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
CN116969936A (zh) 2020-04-15 2023-10-31 百济神州有限公司 Bcl-2抑制剂
EP4129998A4 (en) * 2020-04-29 2024-05-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. CRYSTAL OF A TRIFLUOROMETHYL/CHLORODISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR
CN114736203A (zh) * 2021-01-07 2022-07-12 南京天印健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
CN117616023A (zh) * 2021-04-13 2024-02-27 爱新医药科技(香港)有限公司 Bcl-2或bcl-2/bcl-xl调节剂及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4126937A1 (de) * 1991-08-10 1993-02-11 Basf Ag Salicyl(thio)etherderivate, verfahren und zwischenprodukte zu ihrer herstellung
WO1993004046A1 (en) * 1991-08-19 1993-03-04 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
EP1019385B1 (en) 1995-09-15 2004-01-14 PHARMACIA & UPJOHN COMPANY Aminoaryl oxazolidinone n-oxides
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
CN1195735C (zh) * 1998-02-04 2005-04-06 诺瓦提斯公司 抑制使基质退化的金属蛋白酶的磺酰氨基衍生物
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
CN1425004A (zh) * 2000-03-21 2003-06-18 宝洁公司 含杂环侧链的n－取代的金属蛋白酶抑制剂
UY26942A1 (es) * 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
JP4336678B2 (ja) 2003-09-04 2009-09-30 株式会社日立超エル・エス・アイ・システムズ 半導体装置
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
RU2263666C1 (ru) * 2004-04-08 2005-11-10 Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") Гетероциклилсульфиновые кислоты и их производные, фокусированная библиотека и фармацевтическая композиция
EP1737850B1 (en) 2004-04-19 2007-10-03 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
WO2006009869A1 (en) * 2004-06-17 2006-01-26 Infinity Pharmaceuticals, Inc. Coumpounds and methods for inhibiting the interaction of bcl proteins with binding partners
ES2325401T3 (es) 2004-07-20 2009-09-03 Symed Labs Limited Intermedios novedosos para linezolid y compuestos relacionados.
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
JP5046942B2 (ja) 2004-09-30 2012-10-10 テイボテク・フアーマシユーチカルズ Ｈｃｖ阻害性の二環式ピリミジン類
TWI337182B (en) * 2005-05-12 2011-02-11 Abbott Lab Apoptosis promoters
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US20080182845A1 (en) 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
EP2121641B1 (en) 2007-02-15 2014-09-24 F. Hoffmann-La Roche AG 2-aminooxazolines as taar1 ligands
AU2008242703B2 (en) 2007-04-19 2011-08-18 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
JP2010540635A (ja) 2007-10-02 2010-12-24 コンサート ファーマシューティカルズ インコーポレイテッド ピリミジンジオン誘導体
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
EP2212298B1 (en) 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090131363A1 (en) 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань

Also Published As

Publication number Publication date
ZA201103807B (en) 2012-02-29
IL247183A0 (en) 2016-09-29
EP2376197B1 (en) 2017-02-15
BRPI0922314A2 (pt) 2020-11-17
KR20110099027A (ko) 2011-09-05
KR101683561B1 (ko) 2016-12-08
EP2376197A2 (en) 2011-10-19
JP2015107991A (ja) 2015-06-11
UY32681A (es) 2011-02-28
ES2622344T3 (es) 2017-07-06
MX2011005925A (es) 2011-06-16
AU2009322269A1 (en) 2011-06-30
EP3112361A1 (en) 2017-01-04
TWI600643B (zh) 2017-10-01
PE20120136A1 (es) 2012-03-25
DOP2011000155A (es) 2011-10-31
MX362778B (es) 2019-02-11
WO2010065824A2 (en) 2010-06-10
KR20160140981A (ko) 2016-12-07
UA108193C2 (uk) 2015-04-10
TW201538484A (zh) 2015-10-16
DOP2015000043A (es) 2015-04-30
CN106008466A (zh) 2016-10-12
ECSP11011173A (es) 2011-08-31
CR20110352A (es) 2011-10-27
JP6034411B2 (ja) 2016-11-30
PH12015502017A1 (en) 2017-07-03
RU2527450C2 (ru) 2014-08-27
TW201026680A (en) 2010-07-16
CA2744708A1 (en) 2010-06-10
CO6382143A2 (es) 2012-02-15
NZ592802A (en) 2013-07-26
IL212879A0 (en) 2011-07-31
IL247183B (en) 2020-06-30
SG10201500678RA (en) 2015-03-30
JP2012511015A (ja) 2012-05-17
CA2744708C (en) 2017-07-11
CN102307622B (zh) 2016-08-17
RU2011127232A (ru) 2013-01-10
KR101792640B1 (ko) 2017-11-03
IL212879B (en) 2018-07-31
CL2011001281A1 (es) 2011-11-11
JP5699306B2 (ja) 2015-04-08
WO2010065824A3 (en) 2010-10-07
TWI600650B (zh) 2017-10-01
CR20170289A (es) 2017-09-01
AU2009322269B2 (en) 2015-09-24
MY166546A (en) 2018-07-16
CN106008466B (zh) 2018-12-14
MY179077A (en) 2020-10-27
CN102307622A (zh) 2012-01-04

Similar Documents

Publication Publication Date Title
PE20151091A1 (es) Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes
PE20142316A1 (es) DERIVADOS DE SULFONAMIDA COMO AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CANCER Y ENFERMEDADES INMUNES
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
EA201991770A1 (ru) Способ синтеза ингибитора индоламин-2,3-диоксигеназы
CY1118340T1 (el) Αναστολεις κινασης
RU2014132884A (ru) Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний
MX2021013817A (es) Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
CY1121421T1 (el) Φαρμακοτεχνικες μορφες
JP2014511891A5 (es)
PE20121385A1 (es) DERIVADOS DE SULFONAMIDA COMO AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CANCER Y ENFERMEDADES INMUNES
ME02696B (me) MODULATORI ORFAN RECEPTORA GAMA KOJI U VEZI SA RETINOIDIMA (ROR-GAMA) ZA UPOTREBU U LEĆENJU AUTOIMUNIH l INFLAMATORNIH BOLESTI
JP2014511892A5 (es)
NZ607794A (en) N-acylsulfonamide apoptosis promoters
JP2013543896A5 (es)
HRP20161762T1 (hr) Postupci liječenja primjenom selektivnih bcl-2 inhibitora
PE20191555A1 (es) Agentes inductores de la apoptosis para tratar el cancer y enfermedades inmunes y autoinmunes
CL2008001868A1 (es) Compuestos derivados de n-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades inflamatorias del intestino, enfermedad alergica
CL2011002442A1 (es) Un compuesto n-(4-(4-(3-(3-terc-butil-1-p-tolil-1h-pirazol-5-il)ureido)naftalen-1-iloxi)piridin-2-il)-2-metoxiacetamida o una sal, estereoisomeros y tautomeros del mismo; composicion farmaceutica; y su uso para tratar o prevenir una afeccion seleccionada de epoc, asma e inhibicion del crecimiento y metastasis de tumores, entre otras.
AR087995A1 (es) Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida
HRP20220263T1 (hr) Fenil-2-hidroksi-acetilamino-2-metil-fenil spojevi
CR20120171A (es) Uso de n-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi) fenil)-4-(4-metil-2-tienil)-1-ftalazinamina en el tratamiento de cáncer resistente al agente antimitótico
ECSP10010145A (es) Uso de 3,11b-cis-dihidrotetrabenazina en el tratamiento de la esclerosis múltiple y la mielitis autoinmunitaria
AR068845A1 (es) Composicion farmaceutica que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-((1,3,4-oxadiazol-2-il))fenil)piridin-3-sulfonamida util para el tratamiento del cancer

Legal Events

Date Code Title Description
FG Grant, registration